Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 2Terminated 2

Sponsor Class

OTHER 4

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Head & Neck 4Thoracic 2Other hematologic neoplasm 2Myeloid 2Gynecologic 2CNS 2Tumor-Agnostic 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 2Carcinoma 2Thyroid Neoplasms 1Teratoma, Ovarian 1Struma Ovarii 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 631Radiotherapy 339pembrolizumab 329Cetuximab 284Docetaxel 226Radiotherapy, Intensity-Modulated 221Fluorouracil 199Carboplatin 198Paclitaxel 161Nivolumab 145Gemcitabine 125Magnetic Resonance Spectroscopy 99Radiation 91Drug Therapy 86Capecitabine 77toripalimab 75Surveys and Questionnaires 73Surgical Procedures, Operative 72Biopsy 62durvalumab 61Chemoradiotherapy 52Blood Specimen Collection 52Cyclophosphamide 50Specimen Handling 47camrelizumab 46Radiosurgery 46Erlotinib Hydrochloride 46Standard of Care 44130-nm albumin-bound paclitaxel 44tislelizumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
DNA × Head & Neck × Clear all
NCT04053114 2025-08-29

MOLTHYSO

Institut Bergonié

Withdrawn
GynecologicHead & Neck

Teratoma, Ovarian, Ovarian Neoplasms, Struma Ovarii, Thyroid Neoplasms

NCT02211027 2017-09-07

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

University of Pittsburgh

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00377247 2016-07-11

Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor

University of Pittsburgh

Phase 1 Terminated
5 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma

NCT00898742 2013-04-02

Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Vanderbilt-Ingram Cancer Center

Terminated
58 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡